FDA will approve rare disease treatments based on 'plausible mechanism' evidence instead of requiring clinical trials first
New policy aims to accelerate access to personalized gene therapies for patients with ultra-rare conditions
Policy was partly inspired by a successful treatment of a baby with a rare genetic liver disorder at CHOP
Approximately 30 million Americans suffer from rare diseases that could benefit from this approach
Experts praise the policy but express concerns about potential overapplication to common diseases
📖 Full Retelling
The Food and Drug Administration on Monday, February 23, 2026, unveiled a groundbreaking policy that will allow the agency to approve treatments for rare diseases based on evidence of a 'plausible mechanism' rather than requiring traditional clinical trials first. This initiative aims to accelerate access to cutting-edge gene therapies for patients suffering from extremely rare conditions, addressing a long-standing challenge in medical treatment. Health and Human Services Secretary Robert F. Kennedy Jr. emphasized that the new policy ends the era of patients being told to 'wait for the science to catch up' with their conditions, while FDA Commissioner Marty Makary acknowledged that rare diseases have historically been 'an afterthought' at the agency. The new guidance will apply to diseases where there is a scientific understanding of the genetic defect causing the disorder and how a treatment would address it, particularly crucial for ultra-rare conditions where traditional studies would be impossible due to the small number of affected patients. Dr. Tracy Beth Høeg, director of the FDA's Center for Drug Evaluation and Research, described the day as 'very exciting for patients with very rare diseases,' noting that the policy specifically aims to facilitate advanced technologies like CRISPR gene-editing being developed for genetic blood disorders, cancer, inherited high cholesterol, and some forms of genetic blindness.
🏷️ Themes
Medical Innovation, Regulatory Reform, Personalized Medicine, Rare Disease Treatment
Clinical trials are prospective biomedical or behavioral research studies on human participants designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and ...
Gene therapy is medical technology that aims to produce a therapeutic effect through the manipulation of gene expression or through altering the biological properties of living cells.
The first attempt at modifying human DNA was performed in 1980, by Martin Cline, but the first successful nuclear ge...
# Food and Drug Administration (FDA)
The **Food and Drug Administration (FDA)** is a federal agency within the **United States Department of Health and Human Services (HHS)**. It serves as the primary regulatory body responsible for protecting and promoting public health in the United States.
### ...
Health The FDA creates a quicker path for gene therapies February 23, 2026 3:57 PM ET Rob Stein The Food and Drug Administration will consider approving treatments for rare diseases based on evidence they have a plausible mechanism. Andrew Harnik/AP hide caption toggle caption Andrew Harnik/AP The Food and Drug Administration Monday unveiled the details of a new policy designed to make it easier and quicker for patients with very rare diseases to get cutting-edge treatments. Treatments A promising genetic treatment tailor-made for a baby born with a rare disorder The new guidance would enable the agency to approve new treatments for rare diseases based on evidence for a "plausible mechanism" for how the treatment would work. The policy aims to speed the use of state-of-the-art technologies like gene-editing to create treatments tailored to individual patients suffering from diseases that are so rare that it would be difficult if not impossible to conduct a traditional study first. "For decades families heard the same thing: There are not enough patients. The approval will take too long. You just have to wait for the science to catch up with your child, " Health and Human Services Secretary Robert F. Kennedy Jr. said at a briefing announcing the proposed new policy. "That ends today. Individualized medicine is no longer theoretical." "Historically, rare diseases at the FDA have been an afterthought," added FDA Commissioner Marty Makary said at the briefing. "We've come a long way." The new approach, outlined broadly in November , would apply to diseases where there is a plausible expectation that the treatment would work, such as an understanding of the genetic defect causing the disorder and how the treatment would address it. "Today is a very exciting day for patients with very rare diseases," said Dr. Tracy Beth Høeg, the director of the FDA's Center for Drug Evaluation and Research, at the briefing. Scientists have started developing gene-editing treatments like ...
